Key result
Concomitant exposure to dexamethasone and a DOAC did not significantly increase the risk of thromboembolic events in COVID-19 patients (adjusted OR 1.15; 95% CI 0.32 to 4.18; p=0.48).
Why the study?
Dexamethasone induces CYP3A4, which metabolizes apixaban and rivaroxaban, raising concern that drug interaction could reduce DOAC efficacy and increase thromboembolic risk in COVID-19 patients.
Does concomitant exposure to dexamethasone and apixaban or rivaroxaban increase the risk of thromboembolic events in adults?
Case-Control
Yes
Does concomitant exposure to dexamethasone and apixaban or rivaroxaban increase the risk of thromboembolic events in adults?
Odds Ratio: 1.15 (95% CI 0.32–4.18)
p-value: p=0.48
Concomitant use of dexamethasone and DOACs (apixaban or rivaroxaban) did not show a statistically significant increase in thromboembolic events, though the study was limited by a small sample size.
No TEE risk increase observed with dexamethasone plus DOAC; leaves open a clinically relevant interaction pending larger studies.
Objective The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE. Design We used nested case–control study design. Setting This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repository for COVID-19 in the USA. Participants Study participants were adults over 18 years who were exposed to a DOAC for 10 or more consecutive days. Exposure to dexamethasone was at least 5 or more consecutive days. Primary and secondary outcome measures Our primary exposure variable was concomitant exposure to dexamethasone for 5 or more days after exposure to either rivaroxaban or apixaban for 5 or more consecutive days. We used McNemar’s Χ 2 test and adjusted logistic regression to evaluate association between concomitant use of dexamethasone with either apixaban or rivaroxaban. Results McNemar’s Χ 2 test did not find a discernible association of TEE in patients concomitantly exposed to dexamethasone and a DOAC (χ 2 =0.5, df=1, p=0.48). In addition, a conditional logistic regression model did not find an increase in the risk of TEE (adjusted OR 1.15, 95% CI 0.32 to 4.18). Conclusion This nested case–control study did not find evidence of an association between concomitant exposure to dexamethasone and a DOAC with an increase in risk of TEE. Due to small sample size, an association cannot be completely ruled out.
No takes yet. Share an insight, caveat, or question.
Kravchenko et al. (2022) conducted a case-control in COVID-19. Concomitant exposure to dexamethasone and a DOAC (apixaban or rivaroxaban) was evaluated on Thromboembolic events (TEEs) (adjusted OR 1.15, 95% CI 0.32 to 4.18, p=0.48). Concomitant exposure to dexamethasone and a DOAC did not significantly increase the risk of thromboembolic events in COVID-19 patients (adjusted OR 1.15; 95% CI 0.32 to 4.18; p=0.48).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: